HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) CME: Take the course for this article: Volume 57, Number 9, November 13, 2001 Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grillo, J. A. Articles by Weinstein, R. Search for Related Content PubMed PubMed Citation Articles by Grillo, J. A. Articles by Weinstein, R. Related Collections All Neuromuscular Disease Myasthenia Guillain-Barre syndrome

Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders

From the Divisions of Neurology (Drs. Grillo, Gorson, and Ropper, and J. Lewis) and Hematology (Dr. Weinstein), St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA.

Address correspondence and reprint requests to Dr. K.C. Gorson, Division of Neurology, St. Elizabeth’s Medical Center, 736 Cambridge St., Boston, MA 02135; e-mail: KGorson{at}aol.com

The safety and efficiency of a novel method of rapid-infusion IV immunoglobulin (IVIg) were retrospectively reviewed in 50 patients with neuromuscular disorders. There were 89 adverse events after 341 rapid infusions (26%), 3.5% of which were considered to be major (requiring hospitalization) and 66% minor. All patients recovered without sequelae, and there were no deaths. Fourteen of 17 patients (82%) receiving maintenance therapy preferred rapid IVIg infusion because of its convenience. Rapid-infusion IVIg can be given safely and conveniently in many patients with neuromuscular disorders.

This article has been cited by other articles:

				A. A. Vo, V. Cam, M. Toyoda, D. P. Puliyanda, M. Lukovsky, S. Bunnapradist, A. Peng, K. Yang, and S. C. Jordan Safety and Adverse Events Profiles of Intravenous Gammaglobulin Products Used for Immunomodulation: A Single-Center Experience Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 844 - 852. [Abstract] [Full Text] [PDF]

				S. Shah Pharmacy considerations for the use of IGIV therapy Am. J. Health Syst. Pharm., August 15, 2005; 62(16_Supplement_3): S5 - S11. [Abstract] [Full Text] [PDF]

				J. B. Caress, M. S. Cartwright, P. D. Donofrio, and J. E. Peacock Jr. The clinical features of 16 cases of stroke associated with administration of IVIg Neurology, June 10, 2003; 60(11): 1822 - 1824. [Abstract] [Full Text] [PDF]

				A. H. Ropper Current treatments for CIDP Neurology, April 22, 2003; 60(90083): S16 - 22. [Abstract] [Full Text]

				G. Lemm Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy Neurology, December 24, 2002; 59(90126): S28 - 32. [Abstract] [Full Text]

				T. H. Brannagan III Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies Neurology, December 24, 2002; 59(90126): S33 - 40. [Abstract] [Full Text]

				E. D. Gomperts and F. Darr Rapid infusion of intravenous immunoglobulin in patients with neuromuscular diseases Neurology, May 14, 2002; 58(9): 1444 - 1444. [Full Text] [PDF]

Correspondence: